Clinicopathologic Conference, Systemic Primary Amyloidosis
NEJM 384:363-372, Case 3-2021, 2021
Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Seizing the Clinical Presentation in Adult Onset Stills Disease
Autoimmun Rev 14:472-477, Narula, N.,et al, 2015
Clinical Features, Diagnosis, and Treatment of Disseminated Intravascular Coagulation in Adults
UptoDate, Leung, L.L.K., 2015
The Acquired Metabolic Disorders of the Nervous System, Hashimoto Encephalopathy (Steroid Responsive Encephalopathy Syndrome)
Adams & Victors Principles of Neurology Chp 40, pg 1155, Ropper, A.H.,et al, 2014
Bone Marrow Necrosis and Fat Embolism Syndrome in Sickle Cell Disease: Increased Susceptibility of Patients with Non-SS genotypes and a Possible Association with Human Parvovirus B19 Infection
Blood Rev 28:23-30, Tsitsikas, D.A.,et al, 2014
Clinicopatholic Conference, Acute Infection with Hepatitis B Virus
NEJM 368:1239-1245, Case 10-2013, 2013
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Clinicopath Conf, Intravascular Large-B-Cell Lympoma
NEJM 362:1129-1138, Case 9-2010, 2010
Acute Hepatic Encephalopathy: Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Findings, and Correlation With Plasma Ammonia Level and Clinical Outcome
AJNR 31:1471-1479, McKinney,A.M.,et al, 2010
MRI Findings Associated With Acute Liver Failure
Neurol 72:2130-2131, Fridman,V.,et al, 2009
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007
Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation
NEJM 354:2235-2249, Fischer,S.A.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
An Acute, Life-Threatening, Hypersensitivity Reaction to Riluzole
Neurol 67:2260-2261, Sorenson,E.J.,et al, 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Postpartum Blindness
Lancet 358:1338, Jurgensen,J.S.,et al, 2001
Acute Hepatic Encephalopathy with Diffuse Cortical Lesions
Neuroradiology 43:551-554, Arnold, S.M.,et al, 2001
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Agranulocytosis Associated with Lamotrigine
BMJ 318:1179, DeCamargo,O.A.K., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998
Postpartum Coma
Lancet 351:1700, McCormack,G.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Lamotrigine-Associated Anticonvulsant Hypersentivitiy Syndrome
Neurol 51:1171-1175, Schlienger,R.G.,et al, 1998
Tasmar (tolcapone) Labeling Revisions of Package Insert
Roche Laboratories, , 1998
Carbamazepine Hypersensitivity Syndrome:Report of 4 Cases & Review of Literature
Medicine 74:144-151, DeVriese,A.S.P.,et al, 1995
Anticonvulsant Hypersensitivity Syndrome
Arch Int Med 155:2285-2290, Vittorio,C.C.&Muglia,J.J., 1995
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Clinicopath Conf
Polyarteritis Nodosa, with Neuropathy, Case 40-1994, NEJM 331:1293-130094., , 1994
Hyperthermia and Heatstroke
Hospital Practice 29:65-68, 73, 78-80994., Simon,H.B., 1994
Wilson Disease
Medicine 71:139-164, Brewer,G.J.&Yuzbasiyan-Gurkan,V., 1992
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
Ticlopidine
Editorial, Lancet 337:459-4601991., , 1991
Eosinophilia-Myalgia Syndrome, A Clinical Case Series of 21 Patients
Arch Int Med 151:533-537, Philen,R.M.,et al, 1991